• Leo F Buckley, David P Reardon, Phillip C Camp, Gerald L Weinhouse, David A Silver, Gregory S Couper, and Jean M Connors.
• Department of Pharmacotherapy and Outcomes Science, VCU Pauley Heart Center, Victoria Johnson Research Laboratories, Virginia Commonwealth University, 1200 E Broad Street, West Hospital Rm 520, Richmond, VA 23298, USA. Electronic address: LBuckley2@vcu.edu.
• Heart Lung. 2016 May 1; 45 (3): 232-6.

BackgroundExtracorporeal membrane oxygenation (ECMO) is associated with a significant risk of bleeding and thrombosis. Despite high rates of bleeding and bleeding-related mortality in patients on ECMO, there is little evidence available to guide clinicians in the management of ECMO-associated bleeding.MethodsWe report the use of aminocaproic acid in four patients with bleeding on ECMO and a review of the literature.ResultsHigh D-dimer levels and low fibrinogen levels suggested that an antifibrinolytic agent may be effective as an adjunct to control bleeding. After aminocaproic acid administration, bleeding was controlled in each patient as evidenced by clinical and laboratory parameters. One patient suffered a cardiac arrest and care was withdrawn.ConclusionsIn patients on ECMO with evidence of fibrinolysis, aminocaproic acid may be an effective option to control bleeding and to stabilize clot formation.Copyright © 2016 Elsevier Inc. All rights reserved.

23 keywords...

hide…